Intrathecal Bevacizumab

Uses

How it works

Benefits

Dosage & preparation

Highlighted claims

• Cohort B escalates intrathecal bevacizumab through doses of 5 mg, 10 mg, 25 mg, 37.5 mg, and 50 mg. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• Bevacizumab is an antiangiogenic antibody used in advanced NSCLC. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• Bevacizumab inhibits vascular endothelial growth factor and suppresses tumour growth and tumour-associated angiogenesis. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• In advanced NSCLC, bevacizumab plus chemotherapy has improved progression-free survival and overall survival compared with chemotherapy alone. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
• A retrospective study associated bevacizumab combination therapy, including with intrathecal pemetrexed, with prolonged survival in NSCLC leptomeningeal metastases. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial